GILD Research and Charts

GILD - Gilead Sciences Inc (Healthcare: Drug Manufacturers - General)

Projected Earnings Date: 2026-05-12 (Delayed quote data 2026-02-10)

Last 147.23	Change ⇓ -4.45 (-2.93%)	Volume 10,738,719
	Open 151.47	High 151.87	Low 147.07

8EMA (Daily) 146.60	40EMA (Daily) 133.44	50EMA (Daily) 131.56	STO (Daily) 92.572	MACD Hist (Daily) 0.410
8EMA (Weekly) 137.310	40EMA (Weekly) 120.45	50EMA (Weekly) 117.23	STO (Weekly) 90.724	MACD Hist (Weekly) 2.964


Company Profile
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.